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Mesenchymal stem/stromal cells (MSCs) have been initially
described decades ago as fibroblastic precursors that could
be isolated from the bone marrow and establish cultures of
fibroblastic cells. These fibroblastic cells were shown to
support hematopoiesis in vitro, which is a characteristic of
stromal cells, and, later, to give rise to mature mesenchymal
cells such as bone, cartilage, and fat cells when cultured under
appropriate conditions. The proposition that a mesenchymal
stem cell exists in postnatal bone marrow and other tissues as
blood vessel-associated cells provided further momentum to
research on these cells, as well as divergences on how to call
them. The impetus of using MSCs to replace cells lost in
various types of conditions eventually decreased, as the ther-
apeutic benefits provided by these cells were found to be
mostly due to the secretion of paracrine signaling molecules,
which can be carried by extracellular vesicles. In the mean-
time, MSCs were found to modulate the behavior of immune
cells by means of secretion of molecules that could, in differ-
ent scenarios, inhibit the activation of T cells that promote
adaptive immune responses. Subsequently, the effects of
MSCs on other cells of the immune system were also
described. Today, a number of clinical trials using MSCs to
treat conditions influenced by immune cells are under way.
While preclinical data indicates that MSCs have important
immunomodulatory properties, further studies are still in
progress to increase the knowledge on the differences regard-
ing the action of MSCs on immune cells according to their
tissue of origin, on howMSCs exert their effects on the differ-
ent types of immune cells, and on ways to improve the out-
come of conditions influenced by immune cells when
treated using MSCS.
This special issue was open to basic research manuscripts
and reviews that approached ways to improve the therapeutic
ability of MSCs for the treatment of conditions influenced by
immune cells. Accordingly, two basic research papers on the
interactions between MSCs and immune cells in skin wound
models and three reviews on aspects of the relations between
these cells were accepted. S. Xiao et al. showed that forced
expression of interleukin-10, an anti-inflammatory cytokine,
in human amnion-derived MSCs improves the healing of
full-thickness skin wounds in mice by reducing inflammation
and excessive extracellular matrix deposition while improv-
ing angiogenesis. He and his colleagues focused on the effects
of exosomes, a type of extracellular vesicle, produced by
MSCs isolated from human bone marrow on the polarization
of macrophages in full-thickness skin wounds of mice. Con-
sequently, X. He et al. found that microRNA-223 present in
these exosomes contribute to a proregenerative M2 polariza-
tion in macrophages. B. S. Guerrouahen et al. reviewed
mechanisms underlying communication of MSCs with
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immune cells and discussed clinical applications of MSCs in
diseases mediated by immune cells. F.V. Paladino et al.
reviewed the immunomodulatory properties of Wharton’s
jelly-derived MSCs. Finally, Z. Fábián discussed the effects
of hypoxia on the immunomodulatory properties of the bone
marrow. This group of articles provides a contribution to
better understand and, consequently, improve the therapeu-
tic properties of MSCs for the treatment of conditions influ-
enced by the immune system.
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